Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 01 November 2011
This month's theme is economics and regulatory strategy. Although it is still common for many regulatory professionals to be concerned only with the pure scientific/regulatory side of their work, as the profession has evolved over the years, the ambit of advice they provide has expanded-and with it, their need for knowledge of the entire product lifecycle, from the glimmer in an inventor's eye, through research, trials, approval and even marketing. Many of these stages require an eye to the economics of product development, launch and even postmarket events.
To that end, we have gathered several lead articles this month to give you insight into various aspects of the dollar side of the regulatory business. Regular contributor Philipp Novales-Li gives us an excellent introduction to the whole topic of pharmacoeconmics, reminding us that the link between products and health outcomes can and usually should be quantified. Although no one wants to put a price on human health, reality demands that we measure the effectiveness of products and treatments.
Ray Huml gives us a detailed focus on "patient-centric services," the design of programs to increase effectiveness and lower costs. By taking this perspective, we are able to judge the differences between treatments and preventative steps (including inducing behavioral changes). The article discusses some sophisticated applications of IT technology to healthcare decision making.
Since costs are our focus, we also have an introduction to device clinical trial cost management by Jeffrey Zigler. Device IDE costs have been significantly affected by recent government initiatives and other factors. Zigler gives us the lowdown on the impact of Medicare contracting changes on IDE planning and makes some suggestions for controlling these complications and costs.
Finally, my colleague Thomas Wong and I revisit and debunk a recurring theme about the economics of drug marketing in Canada. Many American regulatory professionals of my acquaintance continue to assume that, because practitioner services are covered by governmental programs in Canada, drugs are similarly "free." This is not the case, and what drugs will be covered by provincial governments in Canada-and to what degree-can have a critical impact on decisions as to whether a particular drug treatment will be made available there.
The most important economic factor to remember is that Regulatory Focus is free to you-a great member benefit of RAPS. Enjoy, with no opportunity cost or other economic consideration!
Tags: economics, In Focus, regulatory
Regulatory Focus newsletters
All the biggest regulatory news and happenings.